In a collaboration aimed at applying cutting edge nanotechnology to its product development, Rexahn Pharmaceuticals has partnered with the University of Maryland's Centre for Nanomedicine and Cellular Delivery to develop cancer-fighting drugs and central nervous system therapies.

The collaboration will focus on finding novel ways of applying the centre's research and nanomedicine expertise to improve the pharmaceutical properties of Rexahn's drugs in development, states the company release.

Dr. Chang Ahn, chairman and CEO of Rexahn said, "The partnership with the University of Maryland will help expand our candidate pipeline and allow us to provide more targeted, efficient and potent therapies for patients. Both are key components of our business strategy."

According to Natalie Eddington, chair of the Department of Pharmaceutical Sciences and professor in the School of Pharmacy, this academic-industrial partnership fosters an interdisciplinary approach to the development of effective chemotherapeutic agents.

The company plans to apply nanodelivery methods advanced through the partnership with the University of Maryland to drugs in its current and future pipelines.